Insert logo of [authorising body](https://www.nice.org.uk/guidance/mpg2/chapter/Recommendations#terms-used-in-the-guideline)

|  |
| --- |
| This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used. |

**PATIENT GROUP DIRECTION (PGD)**

**Supply of a combined oral hormonal contraceptive (COC) in location/service/organisation**

Version Number 2.2

|  |  |
| --- | --- |
| **Change History** | |
| **Version and Date** | **Change details** |
| Version 1  April 2020 | New template |
| Version 1.1  November 2020 | Minor rewording and highlighting of contents cautions section relating to individuals for whom pregnancy presents an unacceptable risk and those on a pregnancy prevention plan.  Acute porphyria added to exclusion criteria. |
| Version 1.2  March 2022 | Addition of vaping/use of e-cigarettes where reference to smoking within PGD.  Following exclusion criteria updated from 3-6 weeks to less than 6 weeks: ‘Not breastfeeding and less than 6 weeks post-partum with other risk factors for venous thromboembolism (VTE).  Clarification of advice for Zoely® |
| Version 2.0  April 2023 | Updated template – amended references and minor editing and wording changes/clarifications.  Strengthened detail on use in individuals requiring control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection for up to three months. |
| Version 2.1  April 2023 | Exclusion added relating to Zoely® only |
| Version 2.2  October 2023 | Updated PGD development group members. Statement added in exclusion criteria regarding consideration of lactose/sucrose content in individual products. |

Each organisation using this PGD must ensure that it is formally signed by a senior pharmacist, a senior doctor and any other professional group representatives involved in its review and that it is reviewed in line with the organisations’ PGD governance system. The organisation’s governance lead must sign to authorise the PGD on behalf of the authorising organisation to ensure that this document meets legal requirements for a PGD.

**PGD DEVELOPMENT GROUP**

|  |  |
| --- | --- |
| Date PGD template comes into effect: | April 2023 |
| Review date | September 2025 |
| Expiry date: | March 2026 |

This PGD template has been peer reviewed by the Reproductive Health PGDs Short Life Working Group in accordance with their Terms of Reference. It has been approved by the Faculty for Sexual and Reproductive Health (FSRH) in November 2022. Note the working group and approving organisation(s) agreement to the content only applies to the national template and does not extend to any local adaptations made to any of the content which are solely the responsibility of the organisation authorising the PGD. The most up to date version of the template is available here:

<https://www.sps.nhs.uk/home/guidance/patient-group-directions/templates/>

**This section MUST REMAIN when a PGD is adopted by an organisation.**

|  |  |
| --- | --- |
| **Name** | **Designation** |
| Dr Cindy Farmer | Vice President, General Training  Faculty of Sexual and Reproductive Healthcare (FSRH) |
| Michelle Jenkins | Advanced Nurse Practitioner, Clinical Standards Committee  Faculty of Sexual and Reproductive Healthcare (FSRH) |
| Vicky Garner | Deputy Chief Midwife British Pregnancy Advisory Service (BPAS) |
| Gail Rowley | Quality Matron British Pregnancy Advisory Service (BPAS) |
| Katie Girling | British Pregnancy Advisory Service (BPAS) |
| Julia Hogan | CASH Nurse Consultant MSI Reproductive Choices |
| Kate Devonport | National Unplanned Pregnancy Advisory Service  (NUPAS) |
| Chetna Parmar | Pharmacist adviser Umbrella |
| Helen Donovan | Royal College of Nursing (RCN) |
| Carmel Lloyd | Royal College of Midwives (RCM) |
| Clare Livingstone | Royal College of Midwives (RCM) |
| Kirsty Armstrong | National Pharmacy Integration Lead, NHS England |
| Dipti Patel | Local authority pharmacist |
| Emma Anderson | Centre for Pharmacy Postgraduate Education (CPPE) |
| Dr Sarah Pillai | Associate Specialist |
| Alison Crompton | Community pharmacist |
| Andrea Smith | Community pharmacist |
| Lisa Knight | Community Health Services pharmacist |
| Bola Sotubo | NHS North East London ICB pharmacist |
| Tracy Rogers | Director, Medicines Use and Safety, Specialist Pharmacy Service |
| Sandra Wolper | Associate Director Specialist Pharmacy Service |
| Jo Jenkins | Lead Pharmacist PGDs and Medicine Mechanisms Specialist Pharmacy Service |
| Rosie Furner (Working Group Co-ordinator) | Specialist Pharmacist PGDs and Medicine Mechanisms Specialist Pharmacy Service |

**The PGD template is not legally valid until it has had the relevant organisational approval - see below.**

**ORGANISATIONAL AUTHORISATIONS AND OTHER LEGAL REQUIREMENTS**

**This page may be deleted if replaced with a format agreed according to local PGD policy with relevant approvals and authorisation.**

The PGD is not legally valid until it has had the relevant organisational authorisations.

To ensure compliance with the law, organisations must add local authorisation details i.e. clinical authorisations and the person signing on behalf of the authorising organisation. You may either complete details below or delete and use a format agreed according to local PGD policy which complies with PGD legislation and [NICE MPG2 PGD 2017](https://www.nice.org.uk/Guidance/MPG2).

|  |  |  |  |
| --- | --- | --- | --- |
| **Name** | **Job title and organisation** | **Signature** | **Date** |
| **Senior doctor** |  |  |  |
| **Senior pharmacist** |  |  |  |
| **Senior representative of professional group using the PGD** |  |  |  |
| **Person signing on behalf of** [**authorising body**](http://publications.nice.org.uk/patient-group-directions-gpg2/appendix-a-glossary#authorising-body) |  |  |  |

It is the responsibility of the provider organisation to ensure that all legal and governance requirements for using the PGD are met.

To meet legal requirements, authorising organisations must add an Individual Practitioner Authorisation sheet or List of Authorised Practitioners. This varies according to local policy and how the service is managed but this should be a signature list or an individual agreement.

PGDs do not remove inherent professional obligations or accountability. It is the responsibility of each professional to practice only within the bounds of their own competence and in accordance with their own Code of Professional Conduct. Individual practitioners must declare that they have read and understood the Patient Group Direction and agree to supply/administer medication(s) listed only in accordance with the PGD.

**ORGANISATIONS MAY ALSO ADD:**

* Local training and competency assessment documentation
* Other supporting local guidance or information
* Links to local PGD Policy and other supporting guidance
* Audit requirements

Any reference to a Trust protocol (either clinical to be followed as part of the administration of a mediciation with the PGD or for any other purpose) must be referenced and hyperlinked to ensure the practitioner acting under the PGD has direct access to the protocol for reference.

1. **Characteristics of staff**

|  |  |
| --- | --- |
| **Qualifications and professional registration** | Current contract of employment within a Local Authority or NHS commissioned service or an NHS Trust/organisation.  Registered healthcare professional listed in the legislation as able to practice under Patient Group Directions. |
| **Initial training** | The registered healthcare professional authorised to operate under this PGD must have undertaken appropriate education and training and successfully completed the competencies to undertake clinical assessment of patients ensuring safe provision of the medicines listed in accordance with local policy.  Suggested requirement for training would be successful completion of a relevant contraception module/course accredited or endorsed by the FSRH, CPPE or a university or as advised in the RCN training directory.  Individual has undertaken appropriate training for working under PGDs for the supply and administration of medicines. Recommended training - [eLfH PGD elearning programme](https://www.e-lfh.org.uk/programmes/patient-group-directions/)  The healthcare professional has completed training and is up to date with service requirements/specification for safeguarding children and vulnerable adults. (amend as per local policy). |
| **Competency assessment** | * Individuals operating under this PGD must be assessed as competent (see Appendix A) or complete a self-declaration of competence for contraception supply. * Staff operating under this PGD are encouraged to review their competency using the [NICE Competency Framework for health professionals using patient group directions](https://www.nice.org.uk/guidance/mpg2/resources) |
| **Ongoing training and competency** | * Individuals operating under this PGD are personally responsible for ensuring they remain up to date with the use of all medicines and guidance included in the PGD - if any training needs are identified these should be addressed and further training provided as required. * Organisational PGD and/or medication training as required by employing Trust/organisation. |
| The decision to supply any medication rests with the individual registered health professional who must abide by the PGD and any associated organisational policies. | |

1. **Clinical condition or situation to which this PGD applies**

|  |  |
| --- | --- |
| **Clinical condition or situation to which this PGD applies** | * Contraception * Individuals requiring control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection for up to three months. |
| **Criteria for inclusion** | * Individual (age from menarche to up to 50 years) presenting for contraception. * Individuals requiring control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection for up to three months. * Consent given. * A recent, accurate blood pressure recording and BMI should be documented for all individuals prior to first CHC supply and repeated for each subsequent supply. In exceptional circumstances, such as a pandemic, where a remote consultation has to take place and it is not possible to obtain a blood pressure or BMI then then please refer to advice the [FSRH Guideline Combined Hormonal Contraception Section 12.1.1](https://www.fsrh.org/Public/Public/Documents/fsrh-guideline-combined-hormonal-contraception.aspx) |
| **Criteria for exclusion** | * Consent not given. * Individuals under 16 years of age and assessed as not competent using Fraser Guidelines. * Individuals 16 years of age and over and assessed as lacking capacity to consent. * Established pregnancy. Note - risk of pregnancy with a negative pregnancy test is not an exclusion * Known hypersensitivity to an active ingredient or to any constituent of the product - see [Summary of Product Characteristics](https://www.medicines.org.uk/emc) * Some COC products contain lactose/sucrose – individuals with rare hereditary problems of galactose intolerance, total lactase deficiency, fructose intolerance or glucose-galactose malabsorption or sucrase-isomaltase deficiency should not take these medicines.  Where applicable, check product excipients before supplying. * Less than 21 days after childbirth (for deliveries over 24 weeks gestation) * Breastfeeding and less than six weeks postpartum. * Not breastfeeding and less than 6 weeks post-partum with other risk factors for venous thromboembolism (VTE). * Individuals aged 50 years and over. * Significant or prolonged immobility.   **Cardiovascular disease**   * Individuals aged 35 years or more who currently smoke or stopped smoking less than one year ago (this includes vaping and the use of e-cigarettes) * Body Mass Index (BMI) equal to or greater than 35kg/m2 * Blood pressure greater than 140/90mmHg or controlled hypertension * Multiple risk factors for cardiovascular disease (CVD) (such as smoking (includes vaping/use of e-cigarettes), diabetes, hypertension, obesity and dyslipidaemias) * Current or past history of ischaemic heart disease, vascular disease, stroke or transient ischaemic attack * Current or past history of venous thromboembolism * Complicated valvular or congenital heart disease e.g. pulmonary hypertension, history of subacute bacterial endocarditis * First degree relative with venous thromboembolism which first occurred when they were under 45 years of age * Known thrombogenic mutations e.g. factor V Leiden, prothrombin mutation, protein S, protein C and antithrombin deficiencies * Cardiomyopathy with impaired cardiac function * Atrial fibrillation   **Neurological Conditions**   * Current or past history of migraine with neurological symptoms including aura at any age * Migraine without aura; when first attack occurred on a method of contraception containing an estrogen * **Zoely® only** – individuals with a meningioma or a history of meningioma   **Cancers**   * Past or current history of breast cancer * Undiagnosed breast mass (for initiation of method only) * Carrier of known gene mutations associated with breast cancer e.g. BRCA1or 2 * Malignant liver tumour (hepatocellular carcinoma)   **Gastro-intestinal Conditions**   * Viral hepatitis, acute or flare (for initiation only) * Benign liver tumour (hepatocellular adenoma) * Severe decompensated cirrhosis * Gallbladder disease; currently symptomatic or medically managed. * Any bariatric or other surgery resulting in malabsorption. * Cholestasis (related to past combined hormonal contraceptive use)   **Other conditions**   * Imminent planned major surgery (COC should be stopped at least 4 weeks prior to planned major surgery or expected period of limited mobility). * Diabetes with end organ disease (retinopathy, nephropathy, neuropathy) * Positive anti-phospholipid antibodies (with or without systemic lupus erythematosus) * Organ transplant, with complications * Known severe renal impairment or acute renal failure * Acute porphyria * Individuals requiring control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection for longer than 3 months (maximum period of supply under this PGD for this condition)   **Medicines**   * Individuals using enzyme-inducing drugs/herbal products or within 4 weeks of stopping them. * Interacting medicines (other than enzyme inducers), including any medicines purchased – see Drug Interactions section |
| **Cautions including any relevant action to be taken** | * If the individual is less than 16 years of age an assessment based on Fraser guidelines must be made and documented. * If the individual is less than 13 years of age the healthcare professional should speak to local safeguarding lead and follow the local safeguarding policy. * Discuss with appropriate medical/independent non-medical prescriber any medical condition or medication of which the healthcare professional is uncertain. * Individuals taking lamotrigine should be advised that COC may interact with lamotrigine; this could result in reduced seizure control or lamotrigine toxicity. * Consideration should be given to the current disease status of those with severe malabsorption syndromes, such as acute/active inflammatory bowel disease or Crohn’s disease. Although the use of oral contraception is not contra-indicated it may be less effective and so these individuals should be advised to consider Long Acting Reversible Contraception (LARC). * Individuals should be advised that it is possible that medications that induce diarrhoea and/or vomiting (e.g. orlistat, laxatives) could reduce the effectiveness of COC. * **Offer LARC to all individuals, in particular those with medical conditions for whom pregnancy presents an unacceptable risk and those on a pregnancy prevention plan.** * **If an individual is known to be taking a medication which is known to be harmful to pregnancy, a highly effective form of contraception is recommended. Highly effective methods include the LARC methods: copper IUD, LNG-IUD and implant. If a LARC method is unacceptable/unsuitable and a COC is chosen then an additional barrier method of contraception is advised. See** [**FSRH advice**](https://www.fsrh.org/standards-and-guidance/documents/fsrh-ceu-statement-contraception-for-women-using-known/)**.** |
| **Action to be taken if the individual is excluded or declines treatment** | * Explain the reasons for exclusion to the individual and document in the consultation record. * Record reason for declining treatment in the consultation record. * Where required refer the individual to a suitable health service provider if appropriate and/or provide them with information about further options. |

1. **Description of treatment**

|  |  |
| --- | --- |
| **Name, strength & formulation of drug** | * This is a list of generic combined oral contraceptive pills. * This PGD does not restrict which brands can be supplied – local formularies/restrictions should be referred to. * See <http://www.mhra.gov.uk/spc-pil/> or <http://www.medicines.org.uk> for further information and further brand information including full details of adverse effects and interactions. * COC containing ≤30micrograms ethinylestradiol in combination with levonorgestrel or norethisterone is a reasonable first-line choice of CHC to minimise cardiovascular risk.   **Monophasic**   * Ethinylestradiol 20micrograms and desogestrel 150micrograms * Ethinylestradiol 20micrograms and drospirenone 3mg * Ethinylestradiol 20micrograms and gestodene 75micrograms * Ethinylestradiol 30micrograms and desogestrel 150micrograms * Ethinylestradiol 30micrograms and drospirenone 3mg * Ethinylestradiol 30micrograms and gestodene 75micrograms * Ethinylestradiol 30micrograms and levonorgestrel 150micrograms * Ethinylestradiol 35micrograms and norgestimate 250micrograms * Ethinylestradiol 35micrograms and norethisterone 500micrograms * Ethinylestradiol 35micrograms and norethisterone 1mg * Mestranol 50microgram and norethisterone 1mg tablets   **Monophasic every day**   * Ethinylestradiol 20micrograms and drospirenone 3mg + 7 inactive * Ethinylestradiol 30micrograms and gestodene 75micrograms + 7 inactive * Ethinylestradiol 30micrograms and levonorgestrel 150micrograms + 7 inactive * Estradiol (as hemihydrate) 1.5mg and nomegestrol acetate 2.5mg + 4 inactive   **Phasic**   * Ethinylestradiol 30/40/30micrograms and levonorgestrel 50/75/125micrograms * Ethinylestradiol 35micrograms and norethisterone 0.5/1mg   **Phasic every day**   * Estradiol valerate 3/2/2/1mg + dienogest 0/2/3/0mg + 2 inactive * Ethinylestradiol 30/40/30 micrograms and levonorgestrel 50/75/125micrograms + 7 inactive |
| **Legal category** | POM |
| **Route of administration** | Oral |
| **Off label use** | Best practice advice is given by the FSRH and is used for guidance in this PGD and this may vary from the Summary of Product Characteristics (SPC).  This PGD includes inclusion criteria, exclusion criteria and dosage regimen which are outside the market authorisation for many of the available products but which are included within FSRH guidance. Specifically:   * the use of tailored COC regimen is outside the manufacturer’s licence but is supported by the Faculty of Sexual & Reproductive Healthcare (FSRH). The regimes detailed within this PGD are permitted under this PGD. * Use for the control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection.   Medicines should be stored according to the conditions detailed in the Storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions the local pharmacy or Medicines Management team must be consulted. Where medicines have been assessed by pharmacy/Medicines Management in accordance with national or specific product recommendations as appropriate for continued use this would constitute off-label administration under this PGD. The responsibility for the decision to release the affected medicines for use lies with pharmacy/Medicines Management.  Where a medicine is recommended off-label consider, as part of the consent process, informing the individual/parent/carer that the medicine is being offered in accordance with national guidance but that this is outside the product licence. |
| **Dose and frequency of administration** | **Contraception**  FSRH guidance states that COC can either be taken following a standard or tailored regimen.  Individuals should be given information about both standard and tailored COC regimen to broaden contraceptive choice.  **Monophasic COC products/regimen**   * Monophasic COC can either be taken as a standard regimen or in a tailored regimen depending on the choice of the individual. * The regimens which can be advised are detailed below:  |  |  |  | | --- | --- | --- | | **Type of regimen** | **Period of COC use** | **Hormone (pill) free interval** | | **Standard use** | | | | Standard use | 21 days (21 active pills) | 7 days | | **Tailored use** | | | | Shortened hormone-free interval | 21 days (21 active pills) | 4 days | | Extended use (tri-cycling) | 9 weeks (3x21 active pills) | 4 or 7 days | | Flexible extended use | Continuous use (≥21 days) of active pills until breakthrough bleeding occurs for 3–4 days | 4 days | | Continuous use | Continuous use of active pills | None |  * For the monophasic regimen detailed above a single tablet is to be taken at the same time each day starting on day 1-5 of the menstrual cycle with no need for additional precautions. * Individuals should have access to clear information (either written or digital) to support tailored COC use.   **Monophasic everyday, phasic and phasic everyday COC products/regimens**   * For monophasic everyday, phasic and phasic everyday regimens a single tablet is to be taken at the same time each day starting on day 1-5 of the menstrual cycle with no need for additional precautions. The exceptions to this are:   + Qlaira®, which should be started on day 1, or if not, additional precautions should be used for 9 days after starting.   + Zoely®, which should be started on day 1, or if not, additional precautions should be used for 7 days after starting. * Thereafter follow manufacturer’s instructions for individual product use.   **For all COC products/regimens**   * COC can be started at any time after day 5 of the menstrual cycle if it is reasonably certain that the individual is not pregnant. Additional precautions are then required for 7 days after starting (9 days for Qlaira®) * When starting or restarting the CHC as quick start after levonorgestrel emergency contraception, additional contraception is required for 7 days and a pregnancy test should be performed 21 days after the last unprotected sexual intercourse. * In line with FSRH guidance individuals using hormonal contraception should delay restarting their regular hormonal contraception for 5 days following ulipristal acetate use. Avoidance of pregnancy risk (i.e. use of condoms or abstain from intercourse) should be advised until fully effective. For COC this is 7 days after re-starting this method. If, in a current user, two pills are missed in the first week of pill taking, it **may** be appropriate to offer UPA-EC. Discuss with a prescriber in this specific circumstance. * For guidance on changing from one contraceptive method to another, and when to start after an abortion and postpartum, refer to the FSRH guidance.   **Control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection.**   * Can be taken as a 21 day cycle/7 day pill free interval or continuously without a pill free interval |
| **Duration of treatment** | **Contraception**  For as long as the individual requires COC and has no contraindications to its use.  **Control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection**  Three months. |
| **Quantity to be supplied** | **Contraception**   * Supply of up to twelve months in appropriately labelled original packs. * For all supplies be aware that the regimen to be taken may not be reflected in the dosage information printed on the product packaging or within the supplied PIL – ensure full details of regimen to be followed are supplied.   **Control of problematic bleeding caused by the subdermal implant, IUS or medroxyprogesterone injection.**   * Supply of up to three months in appropriately labelled original packs. * For all supplies be aware that the regimen to be taken may not be reflected in the dosage information printed on the product packaging or within the supplied PIL – ensure full details of regimen to be followed are supplied. |
| **Storage** | Medicines must be stored securely according to national guidelines. |
| **Drug interactions** | Individuals concurrently prescribed enzyme inducing medicines/herbal products or within 4 weeks of stopping them are excluded from treatment under this PGD and must be referred to an appropriate prescriber:  All concurrent medications, including those purchased should be considered for interactions.  A detailed list of all drug interactions is available in the [BNF](http://www.bnf.org) or the product [SPC](http://www.medicines.org.uk) and FSRH CEU Guidance: Drug Interactions with Hormonal Contraception <https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-drug-interactions-with-hormonal/>  Seek advice from an appropriate clinician/Medicines Advisory Service if required. |
| **Identification & management of adverse reactions** | A detailed list of adverse reactions is available in the individual product SPC, which is available from the electronic Medicines Compendium website: [www.medicines.org.uk](http://www.medicines.org.uk) and BNF [www.bnf.org](http://www.bnf.org)  The following possible adverse effects are commonly reported with COC (but may not reflect all reported adverse effects):   * Nausea * Breast tenderness * Headache and migraine * Temporary disturbances of bleeding patterns * Change in mood including depression * Fluid retention * Change in libido * Skin changes including acne   Serious adverse effects - these are less common but the risks should be discussed with the individual:   * Venous thromboembolic events * Arterial thromboembolic disorders (including ischaemic heart disease) * Strokes (e.g. transient ischaemic attack, ischaemic stroke, haemorrhagic stroke) * Hypertension |
| **Management of and reporting procedure for adverse reactions** | * Healthcare professionals and individuals/carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme on: <http://yellowcard.mhra.gov.uk> * Record all adverse drug reactions (ADRs) in the individual’s clinical record. * Report via organisation incident policy. |
| **Written information and further advice to be given to individual** | * Provide patient information leaflet (PIL) provided with the original pack. * Individuals should be informed about the superior effectiveness of LARC. * Individuals should be provided with written information or a link to a trusted online resource to support safe, effective COC use. * Explain mode of action, side effects, and benefits of the medicine. * Advise about the risks of the medication, including failure rates and serious side effects and the actions to be taken noting that the risks of using COC could outweigh the benefits. * **Serious symptoms:** the individual should stop taking the COC and seek medical help urgently if they experience calf swelling, heat or pain in the calf, shortness of breath, chest pain or haemoptysis. The individual should seek advice if they experience their first ever migraine or develops aura with existing migraine. * Individuals should be advised that current use of COC is associated with a small increased risk of breast cancer which reduces with time after stopping COC * Individuals should be advised that current use of COC for more than 5 years is associated with a small increased risk of cervical cancer; the risk of which reduces over time after stopping COC and is no longer increased by about 10 years after stopping. * Individuals should be advised that current use of COC is associated with an increased risk of VTE/ATE. * Individuals using COC should be advised about reducing periods of immobility during travel. * Individuals trekking to high altitudes (above 4500m or 14500 feet) for periods of more than 1 week may be advised to consider switching to a safer alternative contraceptive method. * Individuals should be advised to stop COC and to switch to an alternative contraceptive method at least 4 weeks prior to planned major surgery or expected periods of limited mobility. * Advise on action if vomiting or severe diarrhoea occurs and missed pill advice - see [FSRH guidance](https://www.fsrh.org/standards-and-guidance/documents/combined-hormonal-contraception/). * Advise that non enzyme inducing antibiotics do not interact with COC and if these are prescribed COC should be continued as normal with no additional precautions required. * Offer condoms and advice on safer sex practices and possible need for screening for sexually transmitted infections (STIs) * Ensure the individual has contact details of local services/sexual health services. * Advise individual to seek advice from a pharmacist, doctor or other prescriber before starting any new medications including those purchased. |
| **Advice / follow up treatment** | * The individual should be advised to seek medical advice in the event of an adverse reaction. * The individual should be encouraged to tell all clinicians that they are taking the supplied medication in the event of other medication/s being prescribed. * The individual should seek further advice if they have any concerns. * Review annually. |
| **Records** | **Record:**   * The consent of the individual and   + If individual is under 13 years of age record action taken   + If individual is under 16 years of age document capacity using Fraser guidelines. If not competent record action taken.   + If individual over 16 years of age and not competent, record action taken * If individual not treated under PGD record action taken * Name of individual, address, date of birth * GP contact details where appropriate * Relevant past and present medical and sexual history, including medication history. * Examination or microbiology finding/s where relevant. * Any known allergies and nature of reaction * Name of registered health professional * Name of medication supplied * Date of supply * Dose supplied * Quantity supplied including batch number and expiry date in line with local procedures. * Advice given about the medication including side effects, benefits, and when and what to do if any concerns * Advice given, including advice given if excluded or declines treatment * Details of any adverse drug reactions and actions taken * Any referral arrangements made * Any supply outside the terms of the product marketing authorisation * Recorded that supplied via Patient Group Direction (PGD)   Records should be signed and dated (or a password controlled e-records) and securely kept for a defined period in line with local policy.  All records should be clear, legible and contemporaneous.  A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy. |

1. **Key references**

|  |  |
| --- | --- |
| **Key references (accessed September 2022, September 2023)** | * Electronic Medicines Compendium <http://www.medicines.org.uk/> * Electronic BNF <https://bnf.nice.org.uk/> * NICE Medicines practice guideline “Patient Group Directions” <https://www.nice.org.uk/guidance/mpg2> * Faculty of Sexual and Reproductive Healthcare (2019, amended 2020) Combined Hormonal Contraception   [FSRH Clinical Guideline: Combined Hormonal Contraception (January 2019, amended October 2023) | FSRH](https://www.fsrh.org/Public/Documents/fsrh-guideline-combined-hormonal-contraception.aspx)   * Faculty of Sexual and Reproductive Health Drug Interactions with Hormonal Contraception – May 2022   [FSRH CEU Guidance: Drug Interactions with Hormonal Contraception (May 2022) | FSRH](https://www.fsrh.org/Public/Documents/ceu-clinical-guidance-drug-interactions-with-hormonal.aspx)   * Faculty of Sexual and Reproductive Healthcare (2016) UK Medical Eligibility Criteria for Contraceptive Use.   [UK Medical Eligibility Criteria for Contraceptive Use (UKMEC) | FSRH](https://www.fsrh.org/Public/Public/Standards-and-Guidance/uk-medical-eligibility-criteria-for-contraceptive-use-ukmec.aspx?hkey=82727ce6-756b-4b88-a5ab-acaf27c48669)   * Faculty of Sexual and Reproductive Healthcare Clinical Guideline: Quick Starting Contraception (April 2017)   [FSRH Clinical Guideline: Quick Starting Contraception (April 2017) | FSRH](https://www.fsrh.org/Public/Documents/fsrh-clinical-guidance-quick-starting-contraception-april-2017.aspx)   * FSRH Clinical Guideline: Problematic Bleeding with Hormonal Contraception (July 2015)  [FSRH Clinical Guideline: Problematic Bleeding with Hormonal Contraception (July 2015) | FSRH](https://www.fsrh.org/Public/Documents/ceu-guidance-problematic-bleeding-hormonal-contraception.aspx?WebsiteKey=f858b086-d221-4a83-9688-824162920b1b) |

**Appendix A – example registered health professional authorisation sheet**

**PGD Name/Version Valid from: Expiry:**

Before signing this PGD, check that the document has had the necessary authorisations. Without these, this PGD is not lawfully valid.

**Registered health professional**

By signing this patient group direction you are indicating that you agree to its contents and that you will work within it.

Patient group directions do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

|  |  |  |  |
| --- | --- | --- | --- |
| **I confirm that I have read and understood the content of this Patient Group Direction and that I am willing and competent to work to it within my professional code of conduct.** | | | |
| **Name** | **Designation** | **Signature** | **Date** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

**Authorising manager**

|  |  |  |  |
| --- | --- | --- | --- |
| **I confirm that the registered health professionals named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of insert name of organisation for the above named health care professionals who have signed the PGD to work under it.** | | | |
| **Name** | **Designation** | **Signature** | **Date** |
|  |  |  |  |

**Note to authorising manager**

Score through unused rows in the list of registered health professionals to prevent additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those registered health professionals authorised to work under this PGD.

Add details on how this information is to be retained according to organisation PGD policy.